Overview of John Wiley & Sons Inc. (WLY)
- Sector: Communication Services
- Industry: Media
- Primary Exchange: New York Stock Exchange (NYSE: WLY)
- Currency: USD
- Market Capitalization: $1.62 billion
- Price‑Earnings Ratio: 16.77
- Stock Price (2026‑03‑03): $30.45
- 52‑Week Range: $28.38 – $47.26
John Wiley & Sons Inc. specializes in the publication of print and electronic scientific, technical, medical, professional, and consumer books, journals, and educational materials. The company operates from Hoboken, New J., and provides subscription services and open‑access content.
Third‑Quarter 2026 Results
| Item | 2026 Q3 | 2025 Q3 | YoY Change |
|---|---|---|---|
| Revenue | $410 million | $404.6 million | +1 % |
| Operating Income | $63 million | $52 million | +21 % |
| Diluted EPS (GAAP) | $0.56 | –$0.43 | Positive transition |
| Adjusted Operating Income | $70 million | $55 million | +22 % |
| Adjusted EBITDA | $105 million | $94 million | +12 % |
| Adjusted EPS | $0.97 | –$0.43 | +19 % |
Key Highlights
- Revenue flat in constant currency – Research and market softness in Learning offset growth in other segments.
- Margin expansion – Adjusted operating margin increased to 17 % (up 280 bps) and Adjusted EBITDA margin rose to 25.7 % (up 250 bps).
- AI & data services – Generated $7 million in AI revenue, reflecting the company’s focus on AI‑driven content analytics.
Strategic Developments
Partnership with OpenEvidence
On 2026‑03‑03, Wiley announced a strategic collaboration with OpenEvidence, a leading medical AI platform. The agreement places Wiley’s peer‑reviewed journals and resources into OpenEvidence’s point‑of‑care interface, allowing physicians to access verified scientific content during clinical decision‑making. This partnership leverages Wiley’s extensive medical literature and OpenEvidence’s AI‑powered search to bridge the gap between research publication and clinical practice.
Investor Expectations
- Analyst consensus for 2026 EPS: $4.00 per share (up from $1.53 in 2025).
- Revenue guidance for 2026: $1.66 billion (slightly lower than the prior year’s $1.68 billion).
Financial Context
- Current share price (2026‑03‑03): $30.45, positioned near the 52‑week low of $28.38, but below the 52‑week high of $47.26.
- P/E ratio: 16.77, indicating valuation relative to earnings.
- Operating leverage: The increase in operating income and margins suggests improved cost management and revenue mix, driven in part by AI initiatives and recurring subscription models.
Conclusion
John Wiley & Sons Inc. reported a modest revenue increase and significant margin expansion in its third quarter of 2026. The company’s focus on AI‑enhanced content delivery, evidenced by its partnership with OpenEvidence and the $7 million AI revenue, positions it to capitalize on growing demand for rapid, evidence‑based clinical information. Despite market softness in some segments, Wiley’s adjusted operating metrics and strategic alliances support a positive outlook for the remainder of the fiscal year.
